Get started
United Therapeutics CorporationUnited Therapeutics CorporationUnited Therapeutics Corporation

United Therapeutics Corporation

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

UTHR trade ideas

Descending TriangleCould break either way. Any triangle can break up or down. It is a consolidation pattern Also a H&S pattern. The talking heads are saying Buy healthcare so be safe, or not. The players will run HC up until it will cave as well. They usually do the same thing over and over and suck us in a long the way. No recommendation/Just some stocks do not live where they are currently living. Doji today so indecision at current price. Price will fight as a rule at the neckline and a strong stock will break it, for a while maybe in a bear market. In a Bull market, you just never know.
NASDAQ:UTHR
by lauralea
UTHR - A Reminder to let trades breathe!!!I went long UTHR on Tuesday, as per the position marked. Its consolidating nicely after breaking out from a previous high and looked really good. Unfortunately I messed the whole thing up!!! I got a pretty nasty entry (got a little too trigger happy on the breakout). My strategy as always but especially so in this market is too keep losses small (typically 5 - 7.5%). I had a stop in place of 6.08%, and got stopped out yesterday before a move to the upside, with a close above the breakout zone. Frustratingly - I could have allowed a 7.5% Stop on the trade, this would have coincided nicely with the 200EMA (giving a little further room to the downside below it). Had I done this, I would still be in the trade. I will keep UTHR on watch. If we see a move back down to the 219 approx area, I will be looking for an entry.
NASDAQ:UTHRLong
by jevanss25
Head and ShouldersPrice is on the neckline. Earnings miss. Entry short with a break of the neckline and a downtrend. No recommendation. United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
NASDAQ:UTHRShort
by lauralea
United Therapeutics Rallied. Now It Pulled BackUnited Therapeutics spent more than a year consolidating around its 2015 highs. Now the biotech may be attempting a breakout. Notice the surge to new all-time highs late last month. The rally followed news that the Food & Drug Administration approved its Tyvaso DPI hypertension drug for two applications. (There were worries of a narrower approval.) UTHR paused for about three weeks and pulled back toward $215. That level is potentially important because it’s near the previous highs last December and January. Has old resistance become new support? Prices have also held the 21-day exponential moving average, which could mean an uptrend has begun. Third, the 50-day simple moving average (SMA) rose above the 200-day SMA on June 10: a “Golden Cross.” Next, stochastics have dipped toward oversold territory. Finally, the macro backdrop may favor UTHR because biotechs are non-cyclical at a time when Jerome Powell is slamming the brakes on the business cycle. They’ve stabilized in the last month – even as the broader market tanked. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options, futures and cryptocurrencies. See our Overview for more. Important Information TradeStation Securities, Inc., TradeStation Crypto, Inc., and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., all operating, and providing products and services, under the TradeStation brand and trademark. You Can Trade, Inc. is also a wholly owned subsidiary of TradeStation Group, Inc., operating under its own brand and trademarks. TradeStation Crypto, Inc. offers to self-directed investors and traders cryptocurrency brokerage services. It is neither licensed with the SEC or the CFTC nor is it a Member of NFA. When applying for, or purchasing, accounts, subscriptions, products, and services, it is important that you know which company you will be dealing with. This content is for informational and educational purposes only. This is not a recommendation regarding any investment or investment strategy. Any opinions expressed herein are those of the author and do not represent the views or opinions of TradeStation or any of its affiliates. Investing involves risks. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options, futures, or digital assets); therefore, you should not invest or risk money that you cannot afford to lose.
NASDAQ:UTHR
by TradeStation